Frontier Biotechnologies Inc.

688221

CNE100005XF5

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-04-10			5-day change	1st Jan Change
19.78 ^CNY	+0.10%		-3.09%	+9.58%

Mar. 19	Frontier Biotechnologies Gets $40 Million Upfront Payment from GSK for Licensing of Two Products; Shares Fell 3%	MT
Mar. 19	China Approves Frontier Biotechnologies' Trial for Chronic Kidney Disease Injection	MT

Chinese Shares Rise as Banks Retain One-Year LPR; Frontier Biotechnologies Jumps 9% on GSK Deal

Published on 02/24/2026 at 02:48 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Frontier Biotechnologies Inc.

Mar. 19	Frontier Biotechnologies Gets $40 Million Upfront Payment from GSK for Licensing of Two Products; Shares Fell 3%	MT
Mar. 19	China Approves Frontier Biotechnologies' Trial for Chronic Kidney Disease Injection	MT
Feb. 27	Frontier Biotechnologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 25	GSK to Buy 35Pharma for $950 Million -- Update	DJ
Feb. 25	GSK to buy 35Pharma for $950 million in CEO Miel's second major deal	RE
Feb. 24	GSK Secures Exclusive Licensing Deal for Frontier's Small Interfering RNA Therapeutics	MT
Feb. 24	Frontier Biotechnologies strikes up to $1 billion deal with GSK	RE
Feb. 24	Chinese Shares Rise as Banks Retain One-Year LPR; Frontier Biotechnologies Jumps 9% on GSK Deal	MT
Feb. 23	Frontier Biotechnologies Signs Licensing Deal With GlaxoSmithKline; Shares Jump 9%	MT
Feb. 19	Deals of the day-Mergers and acquisitions	RE
Jan. 01	Frontier Biotechnologies Gets Nod to Trial Kidney Disease Drug	MT
25-10-30	Frontier Biotechnologies Inc. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-27	Certain A Shares of Frontier Biotechnologies Inc. are subject to a Lock-Up Agreement Ending on 28-OCT-2025.	CI
25-08-29	Frontier Biotechnologies Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-04-29	Frontier Biotechnologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI

Chart Frontier Biotechnologies Inc.

Duration

Period

688221: Dynamic Chart

Frontier Biotechnologies Inc is a China-based company engaged in research and development, production and sales of innovative drugs. The Company's products include Aikening and Combination regiment of Albuvirtide (ABT) + 3BNC117 which is during clinical stage for treatment of human immunodeficiency virus (HIV). Its clinical-stage products also include transdermal analgesic patch AB001 for treating muscle, skeleton and joint pain. The Company conducts its businesses within the China market and to overseas markets.

Employees

302

Sector

Pharmaceuticals

Calendar

Apr. 29 - Earnings release - Annual 2025

More about the company